Industry N Nature Medicine
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry N Nature Medicine
Industry N Nature Medicine
Industry N Nature Biomedical Engineering
Industry
BioCentury
BIOCENTURY | DEALSCSL BUYS INTO ALENTIS’ LEAD AUTOIMMUNE PROGRAM FOR $355M: DEALS REPORTPlus: Genentech brings in Alector’s brain-shuttling ERT; Shionogi/IntraBio; Novartis/Abogen; Sanofi/Regeneron; Novo/Hengrui; and more
Industry
BioCentury
BIOCENTURY | DEALSBUILDING AGAIN IN RARE DISEASES, SHIONOGI PAYS $2B FOR INTRABIOAcquisition would give Japanese pharma a therapy approved for two disorders, including one first-in-disease indication
Industry
Inside Precision Medicine
Even when calories, macronutrients and other nutritional characteristics were closely matched, ultraprocessed foods produced a different insulin and fuel-use response. The study also linked these metabolic differences to altered brain responses to food cues. The post Ultra-Proces…
Industry
GEN
Researchers have uncovered how phage proteases activate CBASS antiphage immunity, revealing a novel bacterial virus-sensing mechanism that could inform development of more effective phage therapies. The post Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway…
Industry
Inside Precision Medicine
Increasing levels of chaperone-mediated autophagy, a process reduced by aging, could improve health by reducing inflammation and the build up of fibrotic tissue in some diseases. The post Reversing a Cellular Aging Process Could Help Treat Fibrotic Disease appeared first on Insid…
Industry
GEN
A study in human monocyte-derived microglia and human brain tissue slices suggests that inflammatory brain conditions, including traumatic brain injury and neurodegenerative diseases such as Alzheimer's disease, could be treated using an existing drug candidate targeting P2X7R. T…
Industry A Applied Clinical Trials
Mixed FSP and FSO models are gaining ground as sponsors seek agility and resource flexibility, but the oversight infrastructure, audit trails, and accountability structures needed to run them well and survive regulatory inspection are consistently lagging behind the model itself.
Industry
Fierce Biotech
"The Next Signal": Where Commercial Pharma Data Is Headed dwunderlin Mon, 10/05/2026 - 14:28 Thu, 10/22/2026 - 14:00 Resource Type Webinar Amy Crowe Stephan Dunning, MBA, MS Commercial teams see patient activity after the fact in healthcare claims. Before a patient is seen, their…
Industry
Fierce Pharma
"The Next Signal": Where Commercial Pharma Data Is Headed dwunderlin Mon, 10/05/2026 - 14:28 Thu, 10/22/2026 - 14:00 Resource Type Webinar Amy Crowe Stephan Dunning, MBA, MS Commercial teams see patient activity after the fact in healthcare claims. Before a patient is seen, their…
Industry P pharmaphorum
Vaxcyte's pneumococcal jab exceeds expectations Phil.Taylor Mon, 05/10/2026 - 18:21
Industry P Pharmaceutical Executive
Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicin…
Industry P pharmaphorum
Lilly's BTK drug Jaypirca joins first-line options in US Phil.Taylor Mon, 05/10/2026 - 16:11
Industry
GEN
HORIBA recently unveiled an Applications Solutions Plaza (ASP) at its Piscataway, New Jersey facility. The ASP allows customers to bring samples for testing or receive on-site demonstrations using modular, laboratory setups configured around specific pain points. The post HORIBA…
Industry
C&EN Pharmaceuticals
Researchers use cell-surface carbohydrate chemistry to guide regenerative cells straight to bone marrow
Industry
BioSpace
Adecto Pharmaceuticals has ceased operations, while Aviceda Therapeutics is in the process of winding down.
Industry
Pharmaceutical Technology
The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, as pharma explores its role on treating ophthalmic conditions.
Industry
MedTech Dive
Mason, who became CEO of the medtech firm a year ago following the death of Karim Bitar, said Convatec’s pace of launching new devices has accelerated for 2026 and 2027.
Industry
Pharmaceutical Processing World
GE HealthCare (Nasdaq: GEHC) aims to bolster its radiopharmaceutical supply chain with a $945 million cash deal to buy Sofie Biosciences and its U.S. network of manufacturing sites. The goal is to obtain last-mile logistics for radioactive imaging agents that have a short half-li…
Industry
MedTech Dive
Four organizations will develop devices for tracking heart disease, inflammation and perimenopause.
Industry P PLOS Biology
by Ruida Zhu, Marcus Grueschow, Marius Moisa, Chao Liu, Christian C. Ruff While humans resemble other primates in terms of motor and perceptual abilities, our behavior is uniquely characterized by morality—the ability to choose our actions based on specific ethical values. The ev…
Industry P PLOS Biology
by Romane Milleville, Gérard Manière, Martine Berthelot-Grosjean, Olivier Lamotte, Yaël Grosjean, Julien Royet, C. Léopold Kurz Animals perceive their immediate environment through their sensory systems. While these systems rely on well-defined neuronal circuits and receptor prot…
Industry
BioPharma Dive
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.
Industry
Clinical Trials Arena
Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes. The post Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority appeared first on Clinical Trials Arena.
Industry
PharmaVoice
Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its DXd franchise.
Industry P Pharmaceutical Executive
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Industry
GEN
Today, the 2026 Nobel Prize for Physiology and Medicine has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics. The post 2026 Nobel Prize for Physiology and Medicine Goes to Optog…
Industry P Pharmaceutical Commerce
McKesson's Chris Van Norman previews his LogiPharma USA keynote on demand signal sharing, AI, and precision distribution for targeted therapies.
Industry P pharmaphorum
Nobel Prize in Medicine awarded to optogenetics trio Phil.Taylor Mon, 05/10/2026 - 12:48
Industry
STAT Biotech
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
Industry P pharmaphorum
Shionogi's diversification continues with $2bn IntraBio buy Phil.Taylor Mon, 05/10/2026 - 11:47
Industry S Science News
New analysis refutes James Watson’s claim he was first to recognize significance of famed photograph 51
Industry
Pharmaceutical Technology
Improving outcomes for patients classed as ‘non-responders’ to GLP-1RA drugs remains a key unmet need within the obesity space.
Industry P pharmaphorum
PharmaMarketing Summit 2027 to Convene America's Top Pharmaceutical Marketing Executives in California Sara.Scarpinati Mon, 05/10/2026 - 10:01
Industry P Pharmaceutical Executive
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
Industry P Pharmaceutical Executive
How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
Industry P pharmaphorum
Novo faces delay in US review of haemophilia drug Phil.Taylor Mon, 05/10/2026 - 09:58
Industry
European Biotechnology
If you ask founders what determines whether they raise capital, most will give you the same answer: great science, compelling clinical data, a large market opportunity and a sensible valuation. For a long time, I would have given exactly the same answer, but I no longer do. After…